
|Articles|June 15, 2003
InSite Vision starts study of ISV-403 treatment
Alameda, CA-InSite Vision Inc. has initiated a phase I clinical study with ISV-403, a treatment for ocular bacterial infections.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement




























